AVAREG: A phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

Neuro-Oncology

Volumn 18, Issue 9, 2016, Pages 1304-1312

  Brandes, Alba A ^a   Finocchiaro, Gaetano ^b   Zagonel, Vittorina ^c   Reni, Michele ^d   Caserta, Claudia ^e   Fabi, Alessandra ^f   Clavarezza, Matteo ^g   Maiello, Evaristo ^h   Eoli, Marica ^b   Lombardi, Giuseppe ^c   Monteforte, Marta ⁱ   Proietti, Emanuela ^j   Agati, Raffaele ^a   Eusebi, Vincenzo ^k   Franceschi, Enrico ^a  

^a BELLARIA HOSPITAL   (Italy)

^b DEPARTMENT OF NEUROSURGERY   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e S MARIA HOSPITAL   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g GALLIERA HOSPITAL   (Italy)

^h CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

ⁱ OPIS   (Italy)

^j ROCHE MILANO RICERCHE   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

AVAREG; bevacizumab; fotemustine; glioblastoma; overall survival

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FOTEMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; EMOTION; FATIGUE; FEMALE; FUNCTIONAL STATUS ASSESSMENT; GLIOBLASTOMA; HUMAN; HYPERTENSION; INSOMNIA; INTESTINE PERFORATION; LEUKOPENIA; LOSS OF APPETITE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PERIANAL ABSCESS; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK; SEX DIFFERENCE; SOCIAL INTERACTION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROGNOSIS; SURVIVAL RATE;

EID: 84985912308     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now035     Document Type: Article

References (25)

1. Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48(10): 1532-1542.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
3. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572-2578.
4. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004;63(7):1281-1284.
5. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26): 3212-3218.
6. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7): 1168-1174.
7. Brandes AA, Tosoni A, Franceschi E, et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2009;64(4):769-775.
8. Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol. 2011;5:117-129.
9. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
10. Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943-953.
11. Wick W, Brandes AA, Gorlia T, et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial. Neuro Oncol. 2015; 17(suppl 5):v1.
12. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
13. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
14. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
15. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
16. EORTC Quality of Life Group. Available at: http://groups. eortc. be/ qol/. Accessed September 25, 2015.
17. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003.
18. Meyer J, Pusch S, Balss J, et al. PCR-and restriction endonucleasebased detection of IDH1 mutations. Brain Pathol. 2010;20(2): 298-300.
19. Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist. 2015;20(2):166-175.
20. Brandes AA, Franceschi E, Gorlia T, et al. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer. 2012;48(6):896-903.
21. Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011; 13(3):353-361.
22. Gorlia T, Stupp R, Brandes AA, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer. 2012;48(8):1176-1184.
23. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25(18):2601-2606.
24. Weller M, Tabatabai G, Kästner B, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DiRECTOR trial. Clin Cancer Res. 2015;21(9): 2057-2064.
25. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.